Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Izrael, Tel Awiw
Ofer Merimsky
41 lat doświadczenia
akredytacje :
Akredytacje :
Dlaczego pacjenci wybierają Izrael na chemioterapię raka prostaty?
Skorzystaj z zaawansowanych rozwiązań chemioterapii raka prostaty w zaufanych klinikach .
| Izrael | Turcja | Austria | |
| Chemioterapia raka prostaty | od $620 | od $1,000 | - |
Day 1: Arrival
Day 2: Pre-operation
Day 3: Chemotherapy
Day 4: Post-operation
Week 1-2: Rehabilitation
Week 3-4: Rehabilitation
Week 5-6: Rehabilitation
Week 6 and beyond: Final result
Please note: Each patient responds to treatment differently, this timeline is an estimate based on general patient experience.
Prof. Merimsky kieruje Oddziałem Onkologii Tkanek Miękkich i Kości w Centrum Medycznym Sourasky, posiadając wieloletnie doświadczenie w leczeniu mięsaków i raka prostaty.
Dr Sarid specjalizuje się w chemioterapii raka prostaty w Centrum Medycznym Sourasky, posiadając ponad 15 lat ukierunkowanego doświadczenia w onkologii.
Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.
He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.
Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.
Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.
He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.
His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.
He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.